biote (BTMD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting will be held virtually on May 13, 2025, with stockholders able to vote and ask questions online.
Stockholders of record as of March 24, 2025, are eligible to participate and vote.
The proxy statement and annual report are available online, and voting can be done via internet, phone, or mail.
Voting matters and shareholder proposals
Two proposals are up for vote: election of two Class III directors (Marc D. Beer and Bret Christensen) and ratification of Deloitte & Touche LLP as independent auditor for 2025.
The board recommends voting for both director nominees and for the auditor ratification.
Stockholders may submit proposals for the 2026 meeting by December 3, 2025, and director nominations between January 13 and February 12, 2026.
Board of directors and corporate governance
The board consists of seven members divided into three classes with staggered three-year terms.
All directors except the Executive Chairman and CEO are considered independent under Nasdaq rules.
The board has Audit, Compensation, and Nominating and Corporate Governance Committees, all composed of independent directors.
The roles of CEO and Executive Chairman are separated, with a lead independent director appointed.
The board met nine times in 2024; most directors attended at least 75% of meetings.
Latest events from biote
- 2025 revenue and margins fell, but investments aim for renewed growth in H2 2026.BTMD
Q4 202511 Mar 2026 - Q2 2024 saw procedure growth, strong margins, narrowed net loss, and reaffirmed 2024 guidance.BTMD
Q2 20242 Feb 2026 - Strong growth, tech-driven wellness expansion, and broad U.S. market opportunity highlighted.BTMD
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q3 revenue up 12.8% to $51.4M; guidance trimmed amid software and hurricane impacts.BTMD
Q3 202414 Jan 2026 - Q4 revenue up 9%, margin gains, and 2025 outlook projects further growth and profitability.BTMD
Q4 202426 Dec 2025 - Stockholders will vote on director elections and auditor ratification, with robust governance in place.BTMD
Proxy Filing2 Dec 2025 - Virtual meeting to elect two directors and ratify auditor, with board support for all proposals.BTMD
Proxy Filing2 Dec 2025 - Q1 net income hit $15.8M on 4.7% revenue growth; 2025 outlook and restructuring reaffirmed.BTMD
Q1 202526 Nov 2025 - Q2 2025: Dietary supplement growth, higher margins, and restructuring drove improved profitability.BTMD
Q2 202523 Nov 2025